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Érika Maria Monteiro dos Santos1, Benedito Mauro Rossi3 and Dirce Maria Carraro1,2*Abstract
Background: Familial adenomatous polyposis (FAP) is a hereditary colorectal cancer syndrome caused by a loss of
function of the APC gene. Large deletions in APC are a common cause of FAP; despite the existence of a variety of
gene dosage detection methodologies, most are labor intensive and time and resource consuming.
Methods: We describe a new duplex qPCR method for gene dosage analysis based on the coamplification of a
target and a reference gene in a SYBR Green reaction, followed by a comparison of the ratio between the target
and the reference peaks of the melting curve for the test (patient) and control samples. The reliability of the
described duplex qPCR was validated for several genes (APC, HPRT1, ATM, PTEN and BRCA1).
Results: Using this novel gene dosage method, we have identified an APC gene deletion in a FAP patient
undergoing genetic testing. Comparative genomic hybridization based on microarrays (aCGH) was used to confirm
and map the extent of the deletion, revealing a 5.2 MB rearrangement (5q21.3-q22.3) encompassing the entire APC
and 19 additional genes.
Conclusion: The novel assay accurately detected losses and gains of one copy of the target sequences,
representing a reliable and flexible alternative to other gene dosage techniques. In addition, we described a FAP
patient harboring a gross deletion at 5q21.3-q22.3 with an unusual phenotype of the absence of mental
impairment and dysmorphic features.
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Familial adenomatous polyposis (FAP) is a dominantly
inherited syndrome characterized by the development of
hundreds of adenomatous colorectal polyps and, conse-
quently, colorectal cancer (CRC) [1,2]. FAP is caused by
mutations in the tumor suppressor gene APC (adenoma-
tous polyposis coli - NM_000038.5) mapped at 5q21-q22
[3,4]. Over 1100 different pathogenic APC mutations
have been reported to date (LOVD Mutation Database -* Correspondence: dirce.carraro@accamargo.org.br
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sense mutations or small deletions and insertions leading
to a truncated protein. Large gene deletions account for
approximately 5% of the germline APC mutations, but
the true prevalence of this type of alteration remains un-
known due to the lack of easy screening techniques [5].
Such alterations have been detected by Southern blot-
ting, MLPAW, competitive and differential qPCR, long-
range PCR and DNA array-based methods [6]. Despite
the great variety of techniques that exist to determine
gene dosage, most of them are labor intensive and time
and resource consuming.
The aim of this study was to develop a novel gene dos-
age method using SYBR Green to confirm a genomicl Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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the coamplification, by duplex PCR, of the target and
reference genes and the comparison of the peaks of the
melting curve (PMc) ratio between patient and controls.
This method was successfully validated and applied to
identify a large genomic deletion encompassing the APC
and 19 additional genes. Thus, this paper presents the
detailed description of this novel gene dosage method,
as well as evaluates the genotype-phenotype correlation
of the APC-deleted patient.
Methods
Samples
The index patient (FAP02) was a Brazilian male with clinic-
ally suspected FAP identified in the Hereditary Colorectal
Cancer Registry of AC Camargo Hospital (São Paulo,
Brazil). His family history was accessed through the index
patient report: his paternal grandmother, his father and one
paternal uncle were affected with polyps and CRC at un-
known ages, and one sister presented with polyps/CRC at
the age of 44 that progressed to liver metastasis. The
affected relatives were deceased; therefore, no biological
material was available for mutation screening. One un-
affected sister and one unaffected niece were available for
genetic testing (Additional file 1: Figure S1). The index pa-
tient was diagnosed with colorectal cancer (T1N0M0) at
the age of 40, and harbored more than 100 synchronous
adenomatous colorectal polyps, including duodenal and
gastric polyps; no signs of other extracolonic manifestations
commonly associated with FAP were observed. The patient
was referred for total proctocolectomy with ileoanal pouch
anastomosis. Examinations performed by a gastroenterolo-
gist and a genetic counselor did not identify any dys-
morphic features or severe mental impairment. The patient
completed his high school education at a regular school,
and then has been working and living independently.
The validation of the gene dosage assay was performed
on samples from 24 healthy controls and three patients
with previously detected genomic alterations. In addition,
the novel missense variant identified in the FAP patient
was screened for in 95 healthy individuals.
This study was executed in compliance with the
Helsinki Declaration and was approved by the ethics com-
mittee of AC Camargo Hospital (approval number: 1169/
08-B). Written informed consent was obtained from all
patients and controls. Genomic DNA from patients and
controls was obtained from blood samples using the Pure-
gene Genomic DNA Isolation Kit (Gentra Systems -
Minneapolis, MN, USA) according to the manufacturer’s
instructions. The DNA concentration was verified with a
NanoDrop 1000 Spectrophotometer (Thermo Fisher
Scientific – Waltham, MA, USA) and DNA samples were
diluted to a concentration of 25 ng/μL. Immediately be-
fore the qPCR assay, the concentration of DNA sampleswas reassessed and they were diluted to a 3.6 ng/μL solu-
tion, from which 5 μL was used in each qPCR reaction (a
total of 18 ng).
PCR and sequence analysis
Sanger sequencing of all APC exons (NM_000038.5), in-
cluding intron-exon boundaries, was performed in the
FAP patient. The amplified fragments were directly
sequenced in both directions using the ABI3130xl se-
quencer (Applied Biosystems - Foster City, USA). The
output results were aligned to the reference sequence
using CLC Bio Main Workbench Software (Muehltal,
Germany). In addition, the presence of the novel mis-
sense variant was screened for in 95 control samples by
PCR followed by sequencing. The primer sequences and
PCR conditions are available upon request.
SYBR-based duplex qPCR
Two main principles were followed for designing the du-
plex qPCR primers, as follows.
1) The total length of the amplicon (including the
primers) should be between 90 and 220 bases.
2) Amplicons for the target and reference genes should
have a minimum of 5°C of difference between their
melting temperatures (Tm), such that a clear
individualization of target and reference gene
melting peaks can be achieved.
In all duplex qPCR reactions, the target and reference
genes were coamplified with 0.15 μM of each primer,
18 ng of DNA and 1X SYBRW Green PCR MasterMix
(Applied Biosystems - Foster City, CA, USA) in a 20 μL
reaction. qPCR was performed using an ABI Prism 7500
detection system (Applied Biosystems - Foster City, CA,
USA). The amplification conditions were as follows: a
10 min preincubation at 95°C followed by 25 cycles of
15 sec at 95°C and one minute at 60°C. The reduced num-
ber of cycles (25) maintains the reaction in the exponential
phase, ensuring that the final amount of amplified product
(demonstrated by the PMc height) is proportional to the
starting amount of template DNA.
After coamplification, the PCR products were sub-
jected to a linear temperature transition from 60°C to
95°C at 0.1°C/s, and melting curves of the decrease of
SYBR Green fluorescence were generated using the ABI
Prism 7500 software (Applied Biosystems - Foster City,
USA). The PMc were identified by plotting the negative
first derivate of the change in fluorescence (–dF/dT, the
rate of change of fluorescence) vs. temperature, allowing
discrimination of the two PMcs, one from the reference
gene and the other from the target gene.
The ratio between the target and reference PMc height
reflects the relative concentration of the target gene in
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of the patient sample with the PMc ratio of the control
sample generates a value that corresponds to the DNA
dosage, revealing whether the target sequence is deleted,
duplicated or normal. Ratios between 0.9 and 1.1 were
considered normal, ratios between 0.6 and 0.7 indicated
deletions of one allele, and ratios above 1.4 indicated
amplifications; ratios outside these intervals were con-
sidered inconclusive and repeated. Values were deter-
mined empirically based on the X chromosome dosage
assay, target genes validation tests and sensibility assay
described below. All the assays included three healthy
controls and were performed in duplicate for patients
and controls.
Validation of this novel gene dosage assay was accom-
plished through the assessment of X chromosome dos-
age in 24 healthy controls (12 males and 12 females) by
determining the ratio between HPRT1 exon 3 (Xq26.1),
as the target gene, and GAPDH intron 7 (12p13), as the
reference gene. A control sample from a female was
used to normalize the ratios. Further validation was per-
formed for different target genes (ATM exon 4, PTEN
exon 2 and BRCA1 exon 24) in samples from patientsFigure 1 Missense mutation and deletion of the APC gene in one FAP
p.Gln2322Arg in APC exon 15 apparently in homozygosis. B: Melt curve of
PMc ratio of APC/GAPDH in the control sample was 1.4 and in the FAP pati
patient, indicating the presence of deletion. C: aCGH chromosome 5 profil
encompasses the entire APC sequence (red circle) and 19 additional genesharboring germline gene deletions and duplications pre-
viously detected by aCGH in other studies of our group.
For the FAP patient, the duplex qPCR was performed
for APC exons 2 and 15 using GAPDH as the reference
gene. After confirming the APC deletion in this patient,
the detection sensitivity of this method was assessed by
mixing five different DNA proportions of the APC-
deleted patient (P) and a healthy control (C). We used
18 ng of DNA in each reaction as follows: 1 P : 0 C
(18 ng P : 0 ng C); 3 P : 1 C (13.5 ng P : 4.5 ng C); 1 P :
1 C (9 ng P : 9 ng C); 1 P : 3 C (4.5 ng P : 13.5 ng C);
and 0 P : 1 C (0 ng P : 18 ng C). All mixtures were sub-
mitted to a duplex qPCR for the APC exon 15 as the
target gene and GAPDH as the reference gene. Experi-
ments were performed in duplicate and data obtained
from the sample containing only DNA from the wild-
type control was used to normalize the PMc ratios.
aCGH experiments and data analysis
Comparative genomic hybridization based on microar-
rays (aCGH) was performed in duplicate for patient
FAP02 using an 180 K whole-genome platform (OGT –
Oxford, UK). Briefly, the samples were labeled with Cy3-patient. A: Chromatogram of the novel missense variant c.6965A>G
duplex qPCR of APC exon 15 and GAPDH intron 7 (reference gene) –
ent it was 0.86, leading to a normalized PMc ratio of 0.61 for the FAP
e of the FAP patient showing a 5.2 Mb deletion at 5q21.3-q22.3 that
.
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hybridization, and washing were performed as recom-
mended by the manufacturer. Data extraction was con-
ducted using the Feature Extraction software (Agilent
Technologies - Santa Clara, USA). Genomic Workbench
software (Agilent Technologies - Santa Clara, USA) was
used to identify the constitutive genomic imbalances
using the statistical algorithm ADM-2 with a sensitivity
threshold of 6.7 and threshold log2 ratios of 0.4 and 1.1
for duplication and high copy number gains, and -0.4
and -1.1 for deletion and homozygous loss, respectively.
Results
A novel homozygous missense variant (c.6965A>G p.
Gln2322Arg – Figure 1A) at exon 15 was identified in
one FAP Brazilian patient undergoing genetic testing of
the APC gene (consulted databases: LOVD -http://www.
lovd.nl/2.0/, dbSNP -http://www.ncbi.nlm.nih.gov/pro-
jects/SNP/, and 1000 Genomes - http://www.1000 gen-
omes.org/). Because FAP is generally characterized by
loss of function mutations in only one allele, the pres-
ence of an undescribed homozygous missense mutation
led us to suspect the existence of a large APC deletion in
the second allele. To test this hypothesis, we developed
and validated a new SYBRW Green-based duplex qPCR
method for gene dosage assessment.
To determine the ability of our technique to dose
chromosomal copy alterations, an X chromosome dos-
age assessment was carried out. Male and female control
samples were evaluated to determine the ratio of the
HPRT1 (Xq26.1) and a reference gene (GAPDH). The
normalized PMc ratios from the male samples ranged
from 0.63 to 0.70, and the ratios from the female sam-
ples ranged from 0.90 to 1.09, indicating the presence of
one X chromosome in the male samples and two in the fe-
male samples (Figure 2A). Visual inspection revealed a
clear reduction in the HPRT1 melting peak in the male
samples relative to that in the female samples (Figure 2B).
To further validate this approach for different target
genes and samples, we used genomic DNA previously
submitted to aCGH in which chromosomal alteration
had been detected (data not shown). The duplex qPCR
was performed in two samples harboring gene deletions
and one sample carrying gene duplication. All genomic
alterations were confirmed by this method: the deleted
samples showed normalized PMc ratios of 0.63 and 0.64
(ATM and PTEN genes, respectively), and the BRCA1
duplicated sample displayed a normalized PMc ratio of
1.5. No overlap between the ratios of any of the wild-
type controls and the ratios of the deleted/duplicated
patients was detected.
For the APC gene, the duplex qPCR was performed
for exons 2 and 15, and gave normalized PMc ratios of
0.67 and 0.61, respectively (Figure 1B), revealing aheterozygous deletion for these APC exons in the FAP pa-
tient. These results were confirmed using standard differ-
ential qPCR with 2-ΔΔCq calculations [7] (see Additional
file 1, Methods), which revealed values of 0.56 and 0.49
for APC exons 2 and 15, respectively. With the purpose of
elucidating the extent of the patient APC deletion, aCGH
was executed using an OGT 180 K whole-genome plat-
form; we detected a 5.2 Mb deletion at 5q21.3-q22.3 –
chr5:g.(107,755,923_107,818,559)_(113,079,145_113,113,
875)del (UCSC Feb. 2009 – GRCh37/hg19) – that encom-
passes the entire APC gene and 19 additional genes
(Figure 1C).
Finally, the sensitivity of this method was assessed by
mixing different proportions of DNA from the deleted
FAP patient and a healthy control (Figure 3A and B).
The results demonstrated that this approach could de-
tect gene dosage alterations even when only 25% of the
DNA carried the heterozygous gene deletion (proportion
4), making this technology capable of detecting mosaic
gene deletions.
Discussion
We have described a simple and inexpensive duplex
qPCR method employing SYBR Green for the assess-
ment of DNA copy number, thereby revealing genomic
duplications and deletions. We also identified a FAP pa-
tient carrying a 5.2 MB deletion in 5q21.3-q22.3 in
addition to a novel missense APC variant (p.Gln2322Arg).
We examined the presence of this undescribed missense
variant in 95 healthy controls, and the alteration was not
detected in any control individual. Because FAP is a dom-
inant condition that is usually caused by truncating muta-
tions or large deletions in the APC gene, we strongly
believe that the causative mutation of the polyposis
observed in this family is the large deletion and that the
missense variant represents a rare neutral variant in the
index patient.
Data regarding clinical characteristics of individuals
carrying whole-gene APC deletions are limited. However,
reported cases have consistently exhibited a degree of
polyposis typical of classical FAP (between 100 and 1000
adenomatous polyps) [8-10]. Our patient was diagnosed
with colorectal cancer at the age of 40 and harbored
more than 100 adenomatous colorectal polyps, including
duodenal and gastric polyps, but no other extracolonic
manifestations commonly associated with FAP (des-
moids, osteomas, cutaneous soft-tissue tumors, dental
abnormalities and CHRPE).
Severe to mild mental impairment is an additional
common phenotype described for FAP individuals with
chromosomal deletions at 5q15-q22, 5q21–q22 and
5q22.1–q31.1, as revised by Readle et al. [9] and
described in the Decipher Database (http://decipher.san-
ger.ac.uk/). Furthermore, those patients have generally
Figure 2 X chromosome dosage assay for validation of the SYBR green duplex qPCR. A: Distribution of the normalized HPRT1 / GAPDH
ratio in 24 control samples (12 females and 12 males); the normalized ratio of the 12 female samples ranged from 0.90 to 1.09, while in the 12
male samples the range was from 0.63 to 0.70, when using a female sample as the control. B: Visual comparison of the melt curve revealing a
reduction of the HPRT1 peak when comparing a male to a female sample.
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ing macrognathia, hypertelorism, a high forehead, a
well-demarcated philtrum, a high arched palate, and
“carp mouth” [10]. The similarities between these
patients raise the possibility that the various phenotypes
represent a contiguous gene syndrome resulting from
partial or complete loss of adjacent genes at 5q, usually
occurring as de novo mutations, with only a few dele-
tions being described as inherited within families [9]. In
these patients, distal deletions (5q22 to 5q31.1) appear
to be associated with severe intellectual disability, while
deletions encompassing the 5q15 to 5q22 region result
in a milder phenotype in terms of both intellectual dis-
ability and physical features [8,9]. In our study, the iden-
tified gross deletion (5q21.3-q22.3) encompasses the
entire APC gene and 19 additional genes and is likely to
have been present in this family for at least three genera-
tions, with a quite unusual phenotype of absence of
mental impairment and dysmorphic features. However,
mild mental impairment cannot be ruled out because no
test was applied to measure the cognitive ability of the
index patient.
To date, the most frequently used techniques to detect
gene copy number alterations include aCGH, which is ex-
pensive; MLPAW, which depends on the availability of the
gene of interest; and quantification using real-time PCR,
which can be performed with intercalating dyes (such as
SYBRW Green) or TaqManW assays. The latter are more fi-
nancially onerous because specific primer and probes sets
for each target gene must be ordered commercially.
Regular SYBRW Green qPCR can be performed either in
a single tube with an internal control fragment (competitivePCR) or using separate reactions for the target and control
genes (differential PCR). However, competitive qPCR is a
time-consuming process that is limited to sets of primers
available from one supplier [11], and the reproducibility of
differential qPCR is inevitably compromised by the variable
efficiency of the PCR itself because small variations in reac-
tion components can greatly influence the final yield of the
amplified product [12,13]. In this sense, a duplex PCR, as
performed in this study, avoids the variations in template
starting amounts that can occur in independent PCR reac-
tions, e.g., due to operator loading errors.
It is important to notice that this method requires
that target and reference gene amplicons display a
minimum difference between the melting temperatures,
such that a clear individualization of the target and the
reference gene melting peaks can be achieved. In our
experience, this minimum difference was ≥5°C. Another
important point to consider is that, similar to other
amplicon-based gene dosage approaches, the duplex
qPCR only assesses the copy number of the amplified
region (90-220 bp), meaning that primers for each exon
should be designed to screen the entire coding-
sequence of a gene.
The novel assay presented here accurately detected
losses and gains of one copy of the target sequence in all
analyses (including mosaics of down to 25% of heterozy-
gous mutated cells). Therefore, this methodology repre-
sents a reliable and flexible alternative both for screening
gene dosage changes and as a validation assay for previ-
ously detected alterations. Nevertheless, validation of this
technique for diagnostic purposes demands additional
analytical studies in larger cohorts and for different genes.
Figure 3 Sensitivity of the duplex qPCR. The sensitivity of this methodology was investigated by mixing different DNA proportions of the
deleted patient and a healthy control. A: First panel presents the melting curve of the five different DNA proportions used (described in the first
line of the table); second and third line show the gene dosage ratio between APC and GAPDH present in each mixed DNA solution and the
respective expected normalized PMc ratio; last line presents mean and standard deviation (SD) of the observed normalized PMc ratio duplicates.
The results demonstrated that this approach could detect gene dosage alterations even when only 25% of the DNA carried the heterozygous
gene deletion (proportion 4 = 1 P : 3 C). B: Linear regression of the observed normalized PMc ratio in relation to the expected PMc ratio,
demonstrating an r² of 0.957.
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We have described a simple and inexpensive duplex qPCR
method employing SYBR Green for the assessment of
DNA copy number, thereby revealing genomic duplica-
tions and deletions. We also reported a FAP patient carry-
ing a 5.2 MB deletion at 5q21.3-q22.3 in addition to anovel missense APC variant (p.Gln2322Arg). This gross
deletion that encompasses the entire APC gene and 19
additional genes is likely to have been present in this fam-
ily for at least three generations, with a quite unusual
phenotype of absence of mental impairment and dys-
morphic features.
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